Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria by Finlay, Andrew Y. et al.
This is an Open Access document downloaded from ORCA, Cardiff University's institutional
repository: http://orca.cf.ac.uk/103461/
This is the author’s version of a work that was submitted to / accepted for publication.
Citation for final published version:
Finlay, Andrew Y., Kaplan, A.P., Beck, L.A., Antonova, E.N., Balp, M.-M., Zazzali, J., Khalil, S.
and Maurer, M. 2017. Omalizumab substantially improves dermatology-related quality of life in
patients with chronic spontaneous urticaria. Journal of the European Academy of Dermatology and
Venereology 10.1111/jdv.14384 file 
Publishers page: http://dx.doi.org/10.1111/jdv.14384 <http://dx.doi.org/10.1111/jdv.14384>
Please note: 
Changes made as a result of publishing processes such as copy-editing, formatting and page
numbers may not be reflected in this version. For the definitive version of this publication, please
refer to the published source. You are advised to consult the publisher’s version if you wish to cite
this paper.
This version is being made available in accordance with publisher policies. See 
http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications
made available in ORCA are retained by the copyright holders.
1 
Omalizumab substantially improves dermatology-related quality of 1 
life in patients with chronic spontaneous urticaria 2 
 3 
Andrew Y. Finlay, CBE FRCP,a Allen P. Kaplan, MD,b Lisa A. Beck, MD,c Evgeniya N. 4 
Antonova, PhD,d Maria-Magdalena Balp, MD, MSce James Zazzali, PhD, MPH,d Sam Khalil, 5 
PhD,e Marcus Maurer, MDf 6 
 7 
a Department of Dermatology and Wound Healing, Cardiff University School of Medicine, 8 
Cardiff University, Cardiff, UK 9 
b Medical University of South Carolina, Charleston, SC, USA 10 
c
 Department of Dermatology, University of Rochester Medical Center, Rochester, NY, USA 11 
d Genentech, Inc., South San Francisco, CA, USA 12 
e Novartis Pharma AG, Basel, Switzerland 13 
f Department of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, Berlin, 14 
Germany 15 
 16 
Short title: Omalizumab and health-related quality of life 17 
 18 
Corresponding author:  19 
Andrew Y. Finlay, CBE FRCP  20 
Department of Dermatology and Wound Healing, Cardiff University School of Medicine, 21 
Cardiff University, Cardiff CF14 4XN, UK.  finlayAY@cardiff.ac.uk  22 
Telephone: +44 2074 2615. Fax: +44 29 2074 4312 23 
 24 
Conflicts of interest: AYF is joint author of the DLQI (Cardiff University) and receives 25 
royalties from its use. AYF is a member of a Novartis UK advisory group and receives 26 
honoraria. 27 
2 
Funding source: Exploratory analyses and writing support for this manuscript were funded 28 
by Novartis Pharma AG. 29 
 30 
Word counts 31 
 Abstract: 311 [limit 300] 32 
 Text: 2684 [limit 3000 excluding abstract, references, figures, and tables]  33 
 34 
Figures/Tables: 4/1 35 
Online only figures/tables: 2/4 36 
IRB status: As this is a post-hoc analysis of data from the phase III studies of omalizumab 37 
in CSU it is not subject to IRB. 38 
Supporting materials:  Permission Document (Hongbo reference). 39 
 40 
 41 
 42 
 43 
 44 
 45 
 46 
 47 
 48 
 49 
 50 
 51 
 52 
3 
ABSTRACT 53 
Background: Chronic spontaneous/idiopathic urticaria (CSU/CIU) has substantial 54 
detrimental effects on health-related quality of life (HRQoL) with an effect comparable to or 55 
worse than many other skin diseases. 56 
Objective: To assess the effect of omalizumab on CSU patients’ HRQoL, measured by the 57 
Dermatology Life Quality Index (DLQI) in three phase III studies ASTERIA I, ASTERIA II, 58 
and GLACIAL. 59 
Methods: A post-hoc analysis examined changes in DLQI scores, distribution of patients 60 
across DLQI bands and the proportion reaching minimal clinically important difference 61 
(MCID) following omalizumab vs placebo. 62 
Results: Omalizumab 300 mg significantly improved total DLQI scores vs placebo, with a 63 
mean decrease from baseline to week 12 of -10.3 vs -6.1 (P<.0001) in ASTERIA I, -10.2 vs -64 
6.1 (P=.0004) in ASTERIA II and -9.7 vs -5.1 (P<.0001) in GLACIAL. A significant shift 65 
from high disease impact on life at baseline towards less impact at week 12 was seen with 66 
omalizumab 300 mg vs placebo (P<.001; all studies). The proportion of patients where 67 
change in mean total DLQI score from baseline to week 12 reached an MCID of ≥4 was 68 
74.1%, 76.0% and 77.2% in ASTERIA I, II and GLACIAL, respectively (P<.01; all studies).  69 
Limitations: Maximum duration of omalizumab treatment was 24 weeks. 70 
Conclusion: This additional analysis assessed the impact of CSU and benefit of treatment 71 
with omalizumab by exploring different facets of DLQI data by treatment arm at multiple 72 
assessment points.  The original aspects of analysis included applying the concept of the 73 
recently validated score for the MCID of the DLQI, changes in DLQI domain scores and in 74 
the distribution of subjects based on validated total DLQI score bands. It showed consistently 75 
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that omalizumab provides significant and clinically relevant improvements in many aspects 76 
of HRQoL that are important to patients with CSU. These results contribute to a better 77 
understanding of the impact of CSU and its treatment on patients and can support clinical 78 
decision making in routine medical practice. 79 
Key words: anti-IgE; chronic idiopathic urticaria; chronic spontaneous urticaria; Dermatology 80 
Life Quality Index; health-related quality of life; omalizumab.  81 
 82 
INTRODUCTION  83 
Chronic spontaneous/idiopathic urticaria (CSU/CIU) (defined as itchy wheals and/or 84 
angioedema for ≥6 weeks with no identifiable specific trigger)1-3 substantially reduces health-85 
related quality of life (HRQoL)1, 4-9 with an effect comparable to or worse than many other 86 
skin diseases.10, 11 CSU adversely affects many aspects of patients’ lives.5, 7, 12 Persistent 87 
itching can cause difficulty sleeping and the resulting chronic fatigue can impair physical and 88 
emotional well-being, work productivity and social functioning.1 CSU patients feel similarly 89 
lacking in energy and are as socially isolated and emotionally upset as patients with ischemic 90 
heart disease, with even greater disturbance in their sleep.7 91 
Second generation H1-antihistamines at licensed doses are the recommended first-line 92 
treatment for CSU. These doses may be increased up to four-fold in patients who do not 93 
respond.2 Omalizumab is a humanized anti-IgE monoclonal antibody approved as add-on 94 
therapy for CSU/CIU in adult and adolescent (≥12 years) patients with inadequate response 95 
to/who remain symptomatic despite H1-antihistamine treatment.13, 14 It is recommended in 96 
the international EAACI/GA2LEN/EDF/WAO urticaria guideline as an add-on third-line 97 
treatment option.2 98 
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Patients’ views on the impact of disease and benefit of treatment can be assessed through 99 
generic or disease-specific patient-reported outcome (PRO) instruments. PRO instruments 100 
developed to assess dermatology-related QoL include the Dermatology Life Quality Index 101 
(DLQI) which was validated for use in CSU.15, 16 The DLQI is a well-established tool that has 102 
been used in numerous studies across multiple countries16-18 and is easy to use in clinical 103 
practice.  104 
Here we report a additional post-hoc analysis of the effect of omalizumab on CSU patients’ 105 
HRQoL using the DLQI score in three phase III studies ASTERIA I,19 ASTERIA II,20 and 106 
GLACIAL.21  107 
METHODS 108 
Study designs 109 
The DLQI was used to assess HRQoL in patients with CSU in three randomized, double-110 
blind, placebo-controlled trials: ASTERIA I,19 ASTERIA II,20 and GLACIAL.21 On entry 111 
into the studies, all patients aged 12-75 years  (18-75 years in Germany) had symptomatic 112 
CSU, with a disease history ≥6 months. Patients in ASTERIA I and ASTERIA II were 113 
receiving H1-antihistamines at approved doses at the time of study enrolment19, 20 and those 114 
in GLACIAL, H1-antihistamines at up to four times the standard dose with H2-antihistamine 115 
and/or leukotriene receptor antagonist.21 In ASTERIA I and II, patients were randomized 116 
1:1:1:1 to receive omalizumab 75 mg, 150 mg, 300 mg, or placebo every 4 weeks for 24 and 117 
12 weeks, respectively (Fig 1). In GLACIAL, patients were randomized 3:1 to receive 118 
omalizumab 300 mg or placebo every 4 weeks for 24 weeks (Fig 1). The number of patients 119 
randomized in ASTERIA I, ASTERIA II and GLACIAL were 319, 323 and 336, 120 
respectively.  121 
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DLQI assessments 122 
The DLQI consists of 10 questions across six domains: symptoms/feelings, daily activities, 123 
leisure, work/school, personal relationships, and treatment.17 Each question is scored from 124 
‘very much’ (score = 3) to ‘not at all’ (0), and an overall score (0–30) is calculated by 125 
summing the individual domain scores.17 A higher score indicates poorer HRQoL.17 DLQI 126 
was measured at baseline and at several time points during the active treatment period (weeks 127 
12 and 24 in ASTERIA I and GLACIAL; week 12 in ASTERIA II) and during the post-128 
treatment follow-up period (week 40 in ASTERIA I and GLACIAL; week 28 in ASTERIA 129 
II).  130 
Absolute (and percentage) change from baseline in mean total DLQI scores following 131 
omalizumab (at approved doses of 150 mg or 300 mg) vs placebo were measured. Change 132 
from baseline to week 12 in mean total DLQI score was a pre-specified secondary endpoint 133 
in the phase III studies.19-21 The current post-hoc analysis also analysed change from baseline 134 
in scores for the 6 individual domains of the DLQI.  135 
Hongbo and co-workers devised bands for DLQI scores. These relate ranges of scores to 136 
meaningful health states and reflect the impact of skin diseases on patients’ lives. Five DLQI 137 
score bands were validated based on input from 1993 patients (Table I), with a total DLQI 138 
score above 10 indicating a very large effect on the patient’s life.22 The distribution of total 139 
DLQI scores across these descriptive bands was analysed at baseline and the different time 140 
points.  141 
A minimal clinically important difference (MCID) of 3–4 points has been estimated for the 142 
DLQI in patients with CSU.23, 24 The MCID is the minimum change in a score of interest 143 
considered important by the patient and mandating a change in the patient’s management.25 144 
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The proportion of patients whose change in mean total DLQI score from baseline reached an 145 
MCID of ≥4 was also measured at different time points.  146 
Statistical analysis 147 
Least square means (LSMs) and 95% confidence intervals (CIs) were calculated for 148 
differences in mean total DLQI score between omalizumab groups and placebo using an 149 
ANCOVA model, controlling for baseline DLQI (<median vs ≥median) and weight (<80 vs 150 
≥80 kg). Statistical significance was evaluated using ANCOVA t-tests. Analyses were 151 
conducted using observed data only, with no imputation for missing scores.  152 
The analysis for the change in the distribution of DLQI score bands was performed for each 153 
trial and each study arm separately by assessing the number and proportion of patients in 154 
each DLQI band at baseline, week 4, 12, 24 and 40 for ASTERIA I and GLACIAL, and at 155 
baseline, week 4, 12, and 28 for ASTERIA II. Chi-square test for significant differences in 156 
the proportions of patients in each DLQI scoring band was performed for each treatment arm 157 
vs placebo. 158 
 159 
For each trial and treatment arm, the proportion of patients who attained a MCID of ≥4 points 160 
on the DLQI total score was assessed at weeks 4, 12, 24 and 40 for ASTERIA I and 161 
GLACIAL, and weeks 4, 12, and 28 for ASTERIA II. Differences in proportions between 162 
treatment arms were analysed for significance using the one-way ANOVA test. 163 
 164 
RESULTS 165 
Baseline characteristics 166 
Baseline demographics and clinical characteristics have been reported previously for the 167 
phase III studies and were similar between treatment arms (Table SI).19-21 The mean total 168 
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DLQI score at baseline ranged from 12.6 to 14.0 across studies reflecting a very large impact 169 
on patients’ lives (Table SI).   170 
In more than half of patients, total DLQI scores at baseline reflected a very large or extremely 171 
large impact of CSU on their lives. The baseline proportion of patients whose disease had a 172 
very large impact on their HRQoL ranged from 42.2% to 53.8% and whose disease had an 173 
extremely large impact ranged from 10.1% to 17.7% across the phase III studies (Figs 3, S1 174 
and S2). CSU had the greatest impact on symptoms and feelings, daily activities and leisure 175 
(Tables SII–SIV). 176 
Change in mean total DLQI score 177 
Omalizumab 300 mg showed statistically and clinically significant improvements in mean 178 
total DLQI scores vs placebo, with a mean change from baseline to week 12 of -10.3 vs -6.1 179 
[LSM treatment difference vs placebo (95% CI) -4.1 (-6.0, -2.2); P < .0001] in ASTERIA I, -180 
10.2 vs -6.1 [-3.8 (-5.9, -1.7); P = .0004] in ASTERIA II and -9.7 vs -5.1 [-4.7 (-6.3, -3.1);  181 
P < .0001] in GLACIAL. This corresponded to a percentage change of -73.6% vs -47.2%, -182 
77.6% vs -44.0% and -72.7% vs -22.5%, respectively (Fig 2).  183 
Omalizumab 150 mg showed statistically significant improvement vs placebo in mean 184 
change of DLQI score from baseline to week 12 in ASTERIA II, but not in ASTERIA I (Fig 185 
2). 186 
Significant improvements in total DLQI scores were observed at week 24 of treatment with 187 
omalizumab 300 mg vs placebo with a mean change from baseline of -10.6 vs -8.1 [-2.0 (-188 
4.0, -0.1); P = .0388] in ASTERIA I and -10.0 vs -6.4 [-3.7 (-5.5, -1.9); P < .0001] in 189 
GLACIAL (Fig 2).  190 
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In all three studies, mean total DLQI scores had increased by the end of the post-treatment 191 
follow-up period (indicating a decrease in HRQoL), although not numerically back to 192 
baseline levels (Fig 2).  193 
Change in DLQI domain scores 194 
Omalizumab 300 mg improved scores in all but one individual DLQI domain between 195 
baseline and week 12, vs placebo; statistically significant improvements were seen in 196 
symptoms/feelings, daily activities, leisure, work and school, and treatment in all three 197 
studies (Tables SII–SIV). Improvement in personal relationships vs placebo was statistically 198 
significant in ASTERIA I and GLACIAL between baseline and week 12 but did not reach 199 
significance in ASTERIA II (Tables SII–SIV). Improvements were seen in all DLQI domain 200 
scores between baseline and week 12 with omalizumab 150 mg vs placebo but none reached 201 
statistical significance in ASTERIA I (Table SII), and in ASTERIA II improvements were 202 
significant only for symptoms and feelings and daily activities (Table SIII). 203 
Improvements in individual domain scores were either continued or maintained with 204 
omalizumab 300 mg or 150 mg by week 24 of treatment in ASTERIA I and GLACIAL 205 
(Tables SII and SIV).  206 
Change in distribution of patients across total DLQI score bands 207 
Treatment with omalizumab at either 300 mg or 150 mg doses led to a redistribution of 208 
patients across total DLQI score bands, towards bands representing better health states. In all 209 
three studies, this shift was significant vs placebo for omalizumab 300 mg at week 12  210 
(P < .001 in ASTERIA I [Fig 3], ASTERIA II [Fig S1] and GLACIAL [Fig S2]) and at week 211 
24 for ASTERIA I and GLACIAL (P < .001; Figs 3 and S2). The shift did not reach 212 
significance following omalizumab 150 mg at week 12. Following treatment with 213 
omalizumab 300 mg, the proportion of patients with DLQI scores corresponding to ‘no 214 
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effect’ on their life at weeks 12 and 24 had increased from 1.2% at baseline to 58.9% and 215 
69.9%, respectively, in ASTERIA I (Fig 3), from 1.3% to 60.0% in ASTERIA II (Figure 216 
S1), and from 0.4% to 57.0% and 57.5% in GLACIAL (Fig S2). 217 
In all three studies, by the end of the post-treatment follow-up period, there was a shift to 218 
score bands describing a greater effect on life, although not numerically back to baseline 219 
levels (Fig 3, S1 and S2). 220 
Changes in mean total DLQI score reaching a MCID of ≥4  221 
Significantly more patients treated with omalizumab 300 mg than placebo had changes in 222 
mean total DLQI scores reaching a MCID of ≥4 from baseline to week 4 (69.1% vs 47.5% in 223 
ASTERIA I; P =.015, 77.2% vs 50.6%; P = .001 in ASTERIA II and 66.3% vs 47.6%;  224 
P =.002 in GLACIAL) and from baseline to week 12 (74.1% vs 46.3% in ASTERIA I;  225 
P =.001, 76.0% vs 53.2%; P =.008 in ASTERIA II and 77.2% vs 47.6%; P < .001 in 226 
GLACIAL) (Fig 4). This clinically significant difference was maintained to week 24 in 227 
GLACIAL (P < .001), but not in ASTERIA I (Fig 4).  228 
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DISCUSSION 229 
In the phase III trials of omalizumab in CSU, the burden of disease was reflected in mean 230 
DLQI scores at baseline with most patients reporting a very large or extremely large impact 231 
on their lives. The initial planned analysis, as published in the original articles19-21, showed 232 
the change in DLQI total score from baseline to week 12. The clinical interpretation of a 233 
simple change in score, while demonstrating effectiveness, may be too simplistic in the 234 
context of clinical practice. In the further exploration reported in this study, three sets of 235 
additional analyses were included involving different aspects of the DLQI by treatment arm 236 
at multiple assessment points: assessing mean changes in individual DLQI domains; 237 
comparing mean scores on the DLQI for patients whose change in DLQI score exceeded the 238 
MCID of the DLQI; and changes in the distributions of patients across DLQI total score 239 
validated descriptor bands. Each of these analyses, representing new and alternative ways of 240 
exploring changes in dermatology-related quality of life, provide additional insights into 241 
patients’ responses to treatment for CSU. The present study provides further insights relevant 242 
for decision making in clinical practice. 243 
In all three studies, 12 weeks’ treatment with omalizumab 300 mg significantly improved 244 
mean total DLQI scores. In ASTERIA I and GLACIAL, which evaluated omalizumab 245 
treatment beyond 12 weeks, this significant improvement was either maintained or increased 246 
vs placebo after 24 weeks (the maximum duration of omalizumab treatment studied). 247 
Assessment of the individual domains of the DLQI allows further understanding of the 248 
impact of dermatological conditions on a patient’s life.7 In ASTERIA I and GLACIAL, 249 
omalizumab 300 mg significantly improved scores from baseline to week 12 in all DLQI 250 
domains, indicating that the improvements seen in the mean total DLQI score were due to a 251 
sum of effects on many aspects of patients’ lives (symptoms/feelings, daily activities, 252 
personal relationships, leisure, work and school, and treatment). Improvement in all domains 253 
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but personal relationships reached statistical significance at week 12 vs placebo in ASTERIA 254 
II.  255 
The beneficial effects of omalizumab 150 mg on DLQI were more modest than with 256 
omalizumab 300 mg, perhaps corresponding to the lesser effect also reported with this dose 257 
vs placebo on itch severity scores.19, 20 258 
At 16 weeks after cessation of omalizumab treatment, improvements observed in both mean 259 
total DLQI scores and individual DLQI domain scores during the treatment period had 260 
lessened (although scores had not numerically increased back to baseline levels). This is in 261 
agreement with the pattern seen in the phase III studies for changes in Urticaria Activity 262 
Score (UAS7), which also increased following discontinuation of omalizumab, but did not 263 
return to baseline levels.19-21 These findings support the hypothesis that longer-term treatment 264 
may be required to sustain the benefit of omalizumab on symptoms and HRQoL and reaffirm 265 
that HRQoL in CSU is linked to disease activity. A good correlation has been seen between 266 
changes in symptoms of CSU (measured using the UAS7) and changes in patients’ HRQoL, 267 
as measured by the DLQI and CU-Q2oL.26  268 
Analysis of the distribution of DLQI scores across descriptive bands which explain and 269 
validate the impact of disease on patients’ lives support the clinical interpretation of results 270 
and advise patients regarding the expected outcomes of omalizumab treatment.22, 24 In all 271 
studies, treatment with omalizumab 300 mg (but not 150 mg) led to a significant shift in the 272 
distribution of DLQI scores to bands showing less to no impact of disease on patients’ lives 273 
vs placebo at week 12. In ASTERIA I and GLACIAL, the shift in DLQI score banding was 274 
still significant vs placebo for omalizumab 300 mg by week 24. Following treatment with 275 
omalizumab 300 mg, the proportion of patients with DLQI scores corresponding to ‘no 276 
effect’ on their life (total DLQI scores of 0-1) at weeks 12 and 24 had increased substantially 277 
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from baseline. In ASTERIA I and GLACIAL, 58.9% and 57% of patients, respectively, 278 
reached a DLQI of 0-1 at week 12, and 69.9% and 57.5% by week 24.  279 
Across the phase III studies, significantly more patients treated with omalizumab 300 mg 280 
than placebo had changes in mean total DLQI scores from baseline reaching the published 281 
MCID of ≥4 for patients with CSU. Omalizumab 300 mg improved mean total DLQI scores 282 
from baseline to week 12 by approximately 10 points (substantially greater than the MCID of 283 
2.97–3.21 points previously estimated in CSU patients and the more stringent threshold of 4 284 
used in this study)23, 24 indicating that the improvements seen in HRQoL are  perceived as 285 
beneficial by patients. Indeed, this was demonstrated by the increased proportion of patients 286 
with DLQI scores corresponding to ‘no effect on their life’.  While mean improvements in 287 
total DLQI from baseline to week 12 with placebo (5–6 points) also exceeded the MCID, the 288 
LSM treatment difference was significant for omalizumab 300 mg vs placebo in ASTERIA I 289 
(P < .0001), ASTERIA II (P = .0004) and GLACIAL (P < .0001). The clinically significant 290 
improvement seen with omalizumab 300 mg was maintained to week 24 in both ASTERIA I 291 
(P = .0388) and GLACIAL (P < .0001).  292 
In conclusion, our analyses demonstrate that omalizumab, particularly at a dose of 300 mg 293 
every 4 weeks, provides significant and clinically relevant improvements in many aspects of 294 
HRQoL that are important to patients with CSU. These results further validate the usefulness 295 
of the DLQI in assessing the impact of CSU and benefit of treatment. 296 
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Fig 1. Designs of the phase III studies of omalizumab in CSU 370 
<Figure uploaded separately> 371 
 Patients in ASTERIA I and ASTERIA II were receiving H1-antihistamines at approved 372 
doses at the time of study enrolment and those in GLACIAL received H1-antihistamines at 373 
up to four times the standard dose with H2-antihistamine and/or leukotriene receptor 374 
antagonist. In ASTERIA I, the introduction of an additional H1-antihistamine was allowed 375 
after week 12, with the aim of reducing patient dropout over the extended treatment period. 376 
In all of the trials, patients were permitted to take diphenhydramine 25 mg as rescue 377 
medication for symptom relief (up to a maximum of 3 doses per 24-hour period, on the basis 378 
of local regulations). 379 
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Fig 2. Change from baseline in mean total DLQI scores during and following treatment in 394 
ASTERIA I, ASTERIA II and GLACIAL 395 
<Figure uploaded separately> 396 
 Omalizumab 150 mg is not licensed for CSU in some countries. Data are for mITT 397 
population. 398 
P values are vs placebo. NSP ≥ .05; *P < .05; **P < .01; ***P < .001, †P < .0001.  399 
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Fig 3. Change in distribution of patients across total DLQI score bands in ASTERIA I 419 
<Figure uploaded separately> 420 
 DLQI is a measure of health-related quality of life, with a higher score indicating greater 421 
impairment of a patient’s quality of life. An overall DLQI score is calculated by summing the 422 
score from10 questions across six different domains, resulting in an overall score from 0 to 423 
30. The scores are then categorized into DLQI bands: 0–1 = no effect; 2–5 = small effect; 6–424 
10 = moderate effect; 11–20 = very large effect; 21–30 = extremely large effect on the 425 
patient’s life (Hongbo et al. 2005).22 426 
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Fig 4. Proportion of patients with a change in mean total DLQI score from baseline reaching 444 
a MCID of ≥4 in ASTERIA I, ASTERIA II and GLACIAL  445 
<Figure uploaded separately> 446 
 P values are vs placebo. NSP ≥ .05; *P < .05; **P < .01; ***P < .001, †P < .0001.  447 
MCID, minimally clinically important difference of ≥4. 448 
